Myriad Genetics said it is partnering with SOPHiA GENETICS to develop a prostate cancer-specific genomic instability score, extending its push into precision oncology. AstraZeneca is also involved, adding weight to Myriad’s expanding diagnostics strategy.
published
Myriad Genetics said it is partnering with SOPHiA GENETICS to develop a prostate cancer-specific genomic instability score, extending its push into precision oncology. AstraZeneca is also involved, adding weight to Myriad’s expanding diagnostics strategy.
Latest documented BWB result
$AAPL market result
I sold the $AAPL $320 Puts for 11/20 - $5.30
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.